Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial
MG Kris, RB Natale, RS Herbst, TJ Lynch Jr, D Prager… - Jama, 2003 - jamanetwork.com
ContextMore persons in the United States die from non–small cell lung cancer (NSCLC)
than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral
gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor
receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a
fraction of patients with NSCLC progressing after chemotherapy experience both a decrease
in lung cancer symptoms and radiographic tumor shrinkages with gefitinib. ObjectiveTo …
than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral
gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor
receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a
fraction of patients with NSCLC progressing after chemotherapy experience both a decrease
in lung cancer symptoms and radiographic tumor shrinkages with gefitinib. ObjectiveTo …